Extended trial tests daily shots to boost growth in kids with dwarfism

NCT ID NCT02724228

Summary

This study follows children with achondroplasia, a genetic condition that causes short stature, to see how safe and effective a daily injection called BMN 111 is over a longer period. It includes about 30 children who have already been taking the drug for two years in a previous study. The main goal is to check for any long-term side effects while also measuring if the treatment continues to help children grow taller and improve their body proportions.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACHONDROPLASIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Ann and Robert H. Lurie Childrens Hospital of Chicago

    Chicago, Illinois, 60611, United States

  • Baylor College of Medicine

    Houston, Texas, 77030, United States

  • Children's Hospital & Research Center Oakland

    Oakland, California, 94609, United States

  • Guys & St. Thomas NHS Foundation Trust Evelina Hospital

    London, SE1 9RT, United Kingdom

  • Harbor - UCLA Medical Center

    Torrance, California, 90509, United States

  • Institut Necker

    Paris, 75015, France

  • Johns Hopkins McKusick - Institute of Genetic Medicine

    Baltimore, Maryland, 21287, United States

  • Murdoch Children's Research Institute

    Parkville, Victoria, 3052, Australia

  • Vanderbilt University

    Nashville, Tennessee, 37232-2578, United States

Conditions

Explore the condition pages connected to this study.